Aspira Women’s Health Inc. (NASDAQ:AWH) Sees Large Decline in Short Interest

Posted by Donald Scott on Feb 1st, 2025

Aspira Women’s Health Inc. (NASDAQ:AWH – Get Free Report) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 356,900 shares, a decline of 18.6% from the December 31st total of 438,500 shares. Currently, 2.9% of the shares of the company are short sold. Based on an average daily volume of 100,900 shares, the short-interest ratio is presently 3.5 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Aspira Women’s Health in a report on Sunday, January 12th. They issued a “hold” rating for the company.

Check Out Our Latest Analysis on AWH

Institutional Trading of Aspira Women’s Health

An institutional investor recently bought a new position in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co acquired a new stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned 0.19% of Aspira Women’s Health at the end of the most recent quarter. Institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Stock Down 6.2 %

Shares of AWH stock traded down $0.02 during trading hours on Friday, hitting $0.38. 166,625 shares of the company’s stock traded hands, compared to its average volume of 70,015. The stock has a market cap of $6.29 million, a PE ratio of -0.31 and a beta of 1.42. The stock’s 50 day simple moving average is $0.67 and its 200 day simple moving average is $0.88. Aspira Women’s Health has a 12 month low of $0.36 and a 12 month high of $5.62.

About Aspira Women’s Health

(Get Free Report)

Aspira Women’s Health, Inc engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.